Scholarlink

Objective <p>To evaluate the association between maternal anti-Ro and anti-La antibody levels and the occurrence of congenital heart block (CHB) in fetuses and newborns.</p> Methods <p>This retrospective cohort study included 182 pregnant women with positive anti-Ro and/or anti-La antibodies who received prenatal care at our tertiary center between 2002 and 2022. Maternal clinical, laboratory, and obstetric variables were analyzed.</p> Results <p>Thirteen fetuses (7.1%) were diagnosed with CHB. Mothers of affected fetuses had significantly higher anti-Ro (median 240 vs. 42; <i>p</i> &lt; 0.001) and anti-La (median 150 vs. 10; <i>p</i> &lt; 0.001) levels. Anti-La positivity was more frequent in the CHB group (76.9% vs. 42.6%; <i>p</i> = 0.017). Lower complement C4 levels (<i>p</i> = 0.008) and disease duration of less than 1&#xa0;year since diagnosis (<i>p</i> = 0.008) were also associated with CHB. Preconception hydroxychloroquine and prednisone use were less frequent in affected pregnancies (<i>p</i> = 0.044 and <i>p</i> = 0.039, respectively).</p> Conclusion <p>Higher maternal anti-Ro and anti-La antibody levels were significantly associated with fetal CHB. Preconception hydroxychloroquine may provide a protective effect. Early diagnosis and specialized care are essential for optimizing neonatal outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Association between maternal anti-Ro and anti-La antibody levels and congenital heart block: a 20-year cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月21日

查看全文
  • Gabriel Duque Pannain,
  • Joelma Queiroz Andrade,
  • Marco Antônio Borges Lopes,
  • Fabrício Marcondes Camargo,
  • Vera Lúcia Jornada Krebs,
  • Werther Brunow de Carvalho,
  • Rossana Pulcinelli Vieira Francisco

摘要

Objective

To evaluate the association between maternal anti-Ro and anti-La antibody levels and the occurrence of congenital heart block (CHB) in fetuses and newborns.

Methods

This retrospective cohort study included 182 pregnant women with positive anti-Ro and/or anti-La antibodies who received prenatal care at our tertiary center between 2002 and 2022. Maternal clinical, laboratory, and obstetric variables were analyzed.

Results

Thirteen fetuses (7.1%) were diagnosed with CHB. Mothers of affected fetuses had significantly higher anti-Ro (median 240 vs. 42; p < 0.001) and anti-La (median 150 vs. 10; p < 0.001) levels. Anti-La positivity was more frequent in the CHB group (76.9% vs. 42.6%; p = 0.017). Lower complement C4 levels (p = 0.008) and disease duration of less than 1 year since diagnosis (p = 0.008) were also associated with CHB. Preconception hydroxychloroquine and prednisone use were less frequent in affected pregnancies (p = 0.044 and p = 0.039, respectively).

Conclusion

Higher maternal anti-Ro and anti-La antibody levels were significantly associated with fetal CHB. Preconception hydroxychloroquine may provide a protective effect. Early diagnosis and specialized care are essential for optimizing neonatal outcomes.